Denali Therapeutics
Price & Volume
Stats
See more52W Range | $12.58-$23.77 |
Market Cap | $2.9B |
Shares Short | 15M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | -$418.7M |
Diluted EPS | -$2.97 |
News
See moreYahoo Finance • 2 days ago
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in
Yahoo Finance • 3 months ago
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
Yahoo Finance • 4 months ago
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
Yahoo Finance • 4 months ago
3 Biotech Stocks With Major 2026 Catalysts
About
CEO | Dr. Ryan J. Watts Ph.D. |
CFO | Dr. Alexander O. Schuth M.D., Ph.D. |
Address | 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 503 |